BR112022021462A2 - Moléculas bifuncionais e métodos de sua utilização - Google Patents

Moléculas bifuncionais e métodos de sua utilização

Info

Publication number
BR112022021462A2
BR112022021462A2 BR112022021462A BR112022021462A BR112022021462A2 BR 112022021462 A2 BR112022021462 A2 BR 112022021462A2 BR 112022021462 A BR112022021462 A BR 112022021462A BR 112022021462 A BR112022021462 A BR 112022021462A BR 112022021462 A2 BR112022021462 A2 BR 112022021462A2
Authority
BR
Brazil
Prior art keywords
bifunctional molecules
methods
domain
specifically binds
target
Prior art date
Application number
BR112022021462A
Other languages
English (en)
Inventor
Wilson STEBBINS Nathan
Andrew Portney Benjamin
Bruno Valeur Eric
Rosenblum Rubens Jacob
Daneshvar Kaveh
Rachael SNEIDER Alexandra
Original Assignee
Flagship Pioneering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Inc filed Critical Flagship Pioneering Inc
Publication of BR112022021462A2 publication Critical patent/BR112022021462A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

MOLÉCULAS BIFUNCIONAIS E MÉTODOS DE SUA UTILIZAÇÃO. A presente revelação se relaciona, de modo geral, às composições de moléculas bifuncionais sintéticas que compreendem um primeiro domínio que se liga especificamente a um ácido ribonucleico-alvo e um segundo domínio que se liga especificamente a um polipeptídeo-alvo, e usos destas.
BR112022021462A 2020-04-21 2021-04-21 Moléculas bifuncionais e métodos de sua utilização BR112022021462A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013462P 2020-04-21 2020-04-21
US202163139916P 2021-01-21 2021-01-21
PCT/US2021/028499 WO2021216786A1 (en) 2020-04-21 2021-04-21 Bifunctional molecules and methods of using thereof

Publications (1)

Publication Number Publication Date
BR112022021462A2 true BR112022021462A2 (pt) 2023-01-17

Family

ID=78269946

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022021462A BR112022021462A2 (pt) 2020-04-21 2021-04-21 Moléculas bifuncionais e métodos de sua utilização
BR112022021469A BR112022021469A2 (pt) 2020-04-21 2021-04-21 Moléculas bifuncionais e métodos de uso das mesmas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022021469A BR112022021469A2 (pt) 2020-04-21 2021-04-21 Moléculas bifuncionais e métodos de uso das mesmas

Country Status (10)

Country Link
US (2) US20230167450A1 (pt)
EP (2) EP4138857A4 (pt)
JP (2) JP2023522961A (pt)
KR (2) KR20230012508A (pt)
CN (2) CN115916262A (pt)
AU (2) AU2021260934A1 (pt)
BR (2) BR112022021462A2 (pt)
CA (2) CA3176196A1 (pt)
IL (2) IL297483A (pt)
WO (2) WO2021216786A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230175038A1 (en) * 2021-12-08 2023-06-08 Janssen Pharmaceutica Nv Crystal structure of btk protein and binding pockets thereof
CN117159546B (zh) * 2023-08-15 2024-05-10 华南农业大学 石蒜碱在制备抗狂犬病的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
NZ545134A (en) * 2003-09-18 2009-06-26 Lilly Co Eli Modulation of eIF4E expression
WO2013012752A2 (en) * 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
PL2920304T3 (pl) * 2012-11-15 2019-07-31 Roche Innovation Center Copenhagen A/S Koniugaty oligonukleotydowe
US20160194368A1 (en) * 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20180085391A1 (en) * 2014-08-08 2018-03-29 Modernatx, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
JP7016323B2 (ja) * 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
WO2018213791A1 (en) * 2017-05-18 2018-11-22 Children's National Medical Center Compositions comprising aptamers and nucleic acid payloads and methods of using the same
EP3781670A4 (en) * 2018-04-20 2021-11-10 The Regents of the University of California FUSION PROTEINS AND RIBONUCLEIC ACIDS FOR TRACKING AND MANIPULATION OF CELLULAR RNA

Also Published As

Publication number Publication date
BR112022021469A2 (pt) 2023-04-04
KR20230014695A (ko) 2023-01-30
IL297482A (en) 2022-12-01
CN115916262A (zh) 2023-04-04
JP2023522961A (ja) 2023-06-01
KR20230012508A (ko) 2023-01-26
WO2021216786A1 (en) 2021-10-28
EP4138857A1 (en) 2023-03-01
AU2021258193A1 (en) 2022-11-24
EP4138857A4 (en) 2024-05-15
IL297483A (en) 2022-12-01
AU2021260934A1 (en) 2022-11-24
EP4138858A1 (en) 2023-03-01
US20230167450A1 (en) 2023-06-01
US20230158156A1 (en) 2023-05-25
CA3176196A1 (en) 2021-10-28
CN115916219A (zh) 2023-04-04
CA3176210A1 (en) 2021-10-28
JP2023522957A (ja) 2023-06-01
WO2021216785A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112022021462A2 (pt) Moléculas bifuncionais e métodos de sua utilização
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
BRPI0923434A2 (pt) Anticorpos que especificamente se liga á angiopoietina-2 (ang-2) humana, seu uso e seu método de produção, composição farmacêutica, ácido nucléico, vetor de expressão, e célula hospedeira procariótica ou eucariótica
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112018075260A2 (pt) inibidores da interação de menina-llm
BR112015021618A2 (pt) métodos e composições para controle de ervas daninhas
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112018068142A2 (pt) corantes nir de alvo ca ix e seus usos
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
BR112018013349A2 (pt) composição adesiva, método de preparação de uma composição adesiva, e produto adesivo
BR112018015690A2 (pt) anticorpos tgfbeta 2
BR112022005026A2 (pt) Conjugados terapêuticos
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112022024045A2 (pt) Moduladores il-17a
BR112022005786A2 (pt) Composto, polissacarídeo reticulado, processo para a preparação de um composto, composição, e, uso de uma composição
BR112016014413A2 (pt) glicosiltransferase que glicosila o ácido flavoquermésico e/ou ácido quermésico
BR112021021099A2 (pt) Formulações de anticorpos estáveis, de baixa viscosidade, e usos das mesmas
BR112015023233A8 (pt) conjugados de hemoglobina, composição farmacêutica e uso de um conjugado de hemoglobina
CO2022005587A2 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
BR112023023223A2 (pt) Degradadores de cdk2 e usos dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing